TELIX Pharmaceuticals (ASX: TLX): Shares Edge Higher as Commercial Growth and Pipeline Progress Continue

Aditi Sarkar

02 September 2026 02:34 PM AEST

TELIX Pharmaceuticals (ASX: TLX): Shares Edge Higher as Commercial Growth and Pipeline Progress Continue

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

TELIX Pharmaceuticals Ltd shares rose 3.67% to AUD 15.83 on 2 September 2026.
The company’s Market Capitalisation was AUD 5380mn, with a one-year share performance of 10.62%.
TELIX reported H1 2026 Revenue of US$477mn, up 22% year over year, with full-year revenue guidance of US$950mn to US$970mn.

TELIX Pharmaceuticals Ltd (ASX: TLX) is back in focus after its shares gained 3.67% to AUD 15.83 on 2 September 2026. The company had a market capitalisation of AUD 5380mn and a one-year share-price performance of 10.62%. The latest move comes as investors assess recent operating developments and the milestones shaping its next phase.

A Commercial-Stage Radiopharmaceutical Company

TELIX Pharmaceuticals is a global radiopharmaceutical company developing and commercialising targeted theranostics and related medical technologies. Its commercial Franchise is anchored by prostate-cancer imaging products, while its development portfolio includes therapeutic candidates targeting prostate cancer, glioblastoma and kidney cancer.

H1 Revenue Reached US$477mn

TELIX reported H1 2026 revenue of US$477mn, up 22% year over year, with full-year revenue guidance of US$950mn to US$970mn. Gross Margin was 55%, while adjusted EBITDA reached US$52mn. The company also received an initial non-refundable US$40mn payment from its Regeneron collaboration, contributing to adjusted EBITDA for the period.

Late-Stage Pipeline Adds Another Growth Layer

The company’s late-stage pipeline includes TLX591-Tx in prostate cancer, TLX101-Tx in recurrent glioblastoma and TLX250-Tx in kidney cancer. TELIX has continued investing heavily in research and development, reporting H1 R&D expenditure of US$124mn. The company has also scheduled an R&D Day in New York for 22 September 2026 to discuss its pipeline and scientific strategy.

Shares Rise as the Story Broadens

TELIX traded at AUD 15.83 on 2 September 2026, up 3.67%. Its market capitalisation was AUD 5.38bn and its one-year performance was 10.62%. The latest gain comes after a period in which investors have been weighing both the company’s commercial performance and the potential of its late-stage therapeutic portfolio.

What Could Come Next

The September R&D Day, continued commercial performance and clinical progress across late-stage programs are likely to be important areas of attention. TELIX is also building its access to US Capital Markets through an ATM Facility established in August, although the company retains discretion over whether and when it is used.

A Measured View on Risk

TELIX operates across commercial pharmaceuticals and clinical-stage development, so future performance can be influenced by product demand, regulatory outcomes, clinical data and research investment. The company is also expanding its global operations, making execution across manufacturing, Supply and commercial markets an ongoing consideration.

FAQs

Q:What was TELIX Pharmaceuticals Ltd’s share price on 2 September 2026?

A:TELIX Pharmaceuticals Ltd traded at AUD 15.83, up 3.67% on the day.

Q:What is TELIX Pharmaceuticals Ltd’s market capitalisation?

A:The market capitalisation was AUD 5380mn.

Q:What does TELIX Pharmaceuticals Ltd do?

A:TELIX Pharmaceuticals is a global radiopharmaceutical company developing and commercialising targeted theranostics and related medical technologies.

Q:What could investors watch next?

A:Investors may focus on the company’s next operating milestones, financial performance and execution of its current strategy.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.